New insights in uremic toxins

被引:164
作者
Vanholder, R [1 ]
Glorieux, G [1 ]
De Smet, R [1 ]
Lameire, N [1 ]
机构
[1] Ghent Univ Hosp, Nephrol Sect, Dept Internal Med, B-9000 Ghent, Belgium
关键词
uremic syndrome; toxins; EUTox;
D O I
10.1046/j.1523-1755.63.s84.43.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The retention in the body of compounds, which normally are secreted into the urine results in a clinical picture, called the uremic syndrome. The retention compounds responsible for the uremic syndrome are called uremic toxins. Only a few of the uremic retention solutes fully conform to a true definition of uremic toxins. Uremic patients develop atheromatotic vascular disease more frequently and earlier than the general population. The classical risk factors seem to be less important. Other factors have been suggested to be at play, and among those uremic toxins are mentioned as potential culprits. The identification, classification and characterization of the solutes responsible for vascular problems seems of utmost importance but is far from complete due to a lack of standardization and organization. The European Uremic Toxin Work Group (EUTox) has as a primary aim to discuss, analyze and offer guidelines in matters related to the identification, characterization, analytical determination and evaluation of biological activity of uremic retention solutes. The final aim remains the development of new strategies to reduce the concentration of the most active uremic solutes. These activities will at first be concentrated on reducing factors influencing cardiovascular morbidity and mortality.
引用
收藏
页码:S6 / S10
页数:5
相关论文
共 17 条
[1]   Sudden and cardiac death rates in hemodialysis patients [J].
Bleyer, AJ ;
Russell, GB ;
Satko, SG .
KIDNEY INTERNATIONAL, 1999, 55 (04) :1553-1559
[2]   Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management [J].
Block, GA ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) :1226-1237
[3]   Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [J].
Cheung, AK ;
Sarnak, MJ ;
Yan, GF ;
Dwyer, JT ;
Heyka, RJ ;
Rocco, MV ;
Teehan, BP ;
Levey, AS .
KIDNEY INTERNATIONAL, 2000, 58 (01) :353-362
[4]  
Fleischmann EH, 2001, CLIN NEPHROL, V56, P221
[5]  
Foley RN, 1998, J AM SOC NEPHROL, V9, P267
[6]   A MECHANISTIC ANALYSIS OF THE NATIONAL COOPERATIVE DIALYSIS STUDY (NCDS) [J].
GOTCH, FA ;
SARGENT, JA .
KIDNEY INTERNATIONAL, 1985, 28 (03) :526-534
[7]   Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis [J].
Iseki, K ;
Fukiyama, K .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (04) :820-825
[8]  
JOHNSON WJ, 1972, MAYO CLIN PROC, V47, P21
[9]   UREMIA - IS UREA MORE IMPORTANT THAN WE THINK [J].
LEE, JA ;
LEE, HA ;
SADLER, PJ .
LANCET, 1991, 338 (8780) :1438-1440
[10]   THE UREA REDUCTION RATIO AND SERUM-ALBUMIN CONCENTRATION AS PREDICTORS OF MORTALITY IN PATIENTS UNDERGOING HEMODIALYSIS [J].
OWEN, WF ;
LEW, NL ;
LIU, Y ;
LOWRIE, EG ;
LAZARUS, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :1001-1006